Insights
Notes from the finance seat.
Short, practical pieces on the questions biotech founders and boards actually ask. No trend pieces, no vendor roundups.
- LatestOctober 1, 2026 · 6 min read
Does the cash reach the readout? What 102 Boston-area biotechs filed for Q2 2026
Most listed biotechs in the Cambridge cluster have cash well past their next clinical catalyst. A small group does not, and the overlap with going concern disclosures is not a coincidence.
- FP&A
- Fundraising
- Tracker
October 1, 2026 · 6 min read
Going concern: what the disclosure means for a biotech, and how to see it coming
A going concern paragraph is not a verdict on your science. It is an accounting test with a fixed twelve month window, and most companies that receive one could have seen it two quarters earlier.
- Audit readiness
- Controller
- Fundraising
September 13, 2026 · 7 min read
What a Series A biotech should have in its books before the first audit
Your first audit is not a test of your science. It is a test of whether the finance function can produce support on demand. Here is what has to exist before fieldwork starts.
- Audit readiness
- Controller
September 13, 2026 · 6 min read
How to accrue CRO costs without surprising the board
Clinical spend is the largest line in a clinical stage P&L, and it arrives on invoices that lag the work by months. A contract map and a monthly conversation with clinical operations fix most of it.
- FP&A
- Clinical finance
September 13, 2026 · 6 min read
Runway math when your milestone is a readout
Cash divided by burn tells you when the money runs out. It does not tell you whether you will have data in hand, and time to raise on it, before that happens. Those are the numbers that matter.
- FP&A
- Fundraising